Almirall SA ALM

VIENNA, October 01, 2026--Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced long-term results from ADlong, a Phase 3b open-label extension study evaluating the efficacy and safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis (AD). The late-breaking results of this long-term clinical study are presented at the 35th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Vienna, A

VIENNA, September 30, 2026--Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology, today announced its scientific programme at the 35th European Academy of Dermatology and Venereology (EADV) Congress, taking place in Vienna from 30 September to 3 October 2026. As Gold Sponsor of this year’s congress, Almirall will present more than 20 abstracts on clinical and real-world evidence spanning atopic dermatitis (AD), psoriasis (PsO) and actinic keratosis (AK), and

The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging populations. Advanced diagnostics, AI, targeted therapies, superficial radiation therapy and electronic brachytherapy are improving early detection and outcomes. North America leads the market, followed by Europe, while Asia-Pacific is expanding rapidly. Key players include Amgen, Regeneron, Almirall and Boehringer Ingelheim. FDA-approved Libtay

BARCELONA, Spain, August 10, 2026--Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology based in Barcelona, today announced a collaboration and licensing agreement with Shenzhen CrystalO Biopharma Technology Co., Ltd. ("CrystalO") to jointly initiate an R&D collaboration for drug discovery in medical dermatology. The collaboration will combine CrystalO's scientific expertise in ion channels with Almirall's experience in medical dermatology research and clinic

Almirall SA (STU:E2Z) reports robust sales growth and improved financial metrics, despite challenges in the U.S. and Germany.

BARCELONA, Spain, July 24, 2026--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its financial results for the first half of 2026. The company delivered solid H1 2026 results, with Net Sales growing 7.5% YoY to €602.7 MM and EBITDA increasing 23.7% YoY to €150.7 MM. The results are in line with Almirall’s long-term growth trajectory, and the company reiterated its full-year 2026 guidance of 9-12% Net Sales growth and EBITDA of €270 MM to €2

BARCELONA, Spain, July 20, 2026--Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced that the European Medicines Agency (EMA) has accepted the submission of the extension of the Marketing Authorisation Application (MAA) of Ebglyss® (lebrikizumab) for the treatment of children and adolescents aged 6 months to <18 years and weighing below 40 kg with moderate-to-severe atopic dermatitis.

Recent performance snapshot Almirall (BME:ALM) has drawn attention after a mixed run for the stock, with modest gains over the past year alongside a decline year to date, prompting investors to reassess its current valuation. The company reports revenue of €1,120.832 and net income of €39.854, with annual revenue growth of 8.44% and net income growth of 27.89%. Recent share performance shows a small gain over the past month and a decline over the past 3 months. See our latest analysis for...

Evotec SE (NASDAQ:EVO) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 4, 2026, Evotec SE (NASDAQ:EVO) announced the nomination of a small molecule preclinical development candidate from its multi-target drug discovery alliance with Almirall focused on medical dermatology. The program is aimed at developing new therapies for immune-mediated […]

Appointment strengthens Vicore's board with nearly four decades of global pharmaceutical leadership as the company advances buloxibutid toward an important late-stage data readout STOCKHOLM, SE / ACCESS Newswire / May 7, 2026 /Vicore Pharma Holding ...

Joint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelines Collaboration leverages Evotec's end-to-end integrated AI/ML-driven R&D capabilities and Almirall's dermatology ...

Why Almirall (BME:ALM) is Back on Watchlists Almirall (BME:ALM) has drawn fresh attention after recent share price moves, with the stock showing a mix of gains over the past month and weaker performance over the past three months. See our latest analysis for Almirall. Recent trading has been mixed, with a 0.79% 1 day share price return and an 11.71% 30 day share price return set against a small year to date share price decline and a 38.46% 1 year total shareholder return. This suggests that...